Multiple sclerosis other diagnostic studies: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
[[Visual evoked potential|visual evoked potential studies]] and anti[[myelin]] [[antibodies]] may be helpful in the [[diagnosis]] of multiple sclerosis. | |||
==Other Diagnostic Studies== | ==Other Diagnostic Studies== | ||
====Visual evoked potential studies==== | ====Visual evoked potential studies==== | ||
Revision as of 14:29, 1 March 2018
|
Multiple sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple sclerosis other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Multiple sclerosis other diagnostic studies |
|
Risk calculators and risk factors for Multiple sclerosis other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
visual evoked potential studies and antimyelin antibodies may be helpful in the diagnosis of multiple sclerosis.
Other Diagnostic Studies
Visual evoked potential studies
Delay in response after stimulation of retina with light is an indicator of a problem in visual tracts due to axonal demyelination.[1] The indication of this test is when patient is not fulfilling MS criteria and is a probable MS case.[2][3]
Antimyelin antibodies
myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) thought to be a predictor of disease progression but some studies denied any relationship between these auto antibodies and disease severity or progression.[4][5][6][7]
References
- ↑ Klistorner A, Arvind H, Nguyen T, Garrick R, Paine M, Graham S, O'Day J, Grigg J, Billson F, Yiannikas C (September 2008). "Axonal loss and myelin in early ON loss in postacute optic neuritis". Ann. Neurol. 64 (3): 325–31. doi:10.1002/ana.21474. PMID 18825673.
- ↑ Chiappa KH (November 1988). "Use of evoked potentials for diagnosis of multiple sclerosis". Neurol Clin. 6 (4): 861–80. PMID 3070342.
- ↑ Matthews WB, Wattam-Bell JR, Pountney E (April 1982). "Evoked potentials in the diagnosis of multiple sclerosis: a follow up study". J. Neurol. Neurosurg. Psychiatry. 45 (4): 303–7. PMC 491364. PMID 7077339.
- ↑ Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (July 2003). "Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event". N. Engl. J. Med. 349 (2): 139–45. doi:10.1056/NEJMoa022328. PMID 12853586.
- ↑ Gaertner S, de Graaf KL, Greve B, Weissert R (December 2004). "Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis". Neurology. 63 (12): 2381–3. PMID 15623705.
- ↑ Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R (January 2007). "Lack of association between antimyelin antibodies and progression to multiple sclerosis". N. Engl. J. Med. 356 (4): 371–8. doi:10.1056/NEJMoa063602. PMID 17251533.
- ↑ Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, Comi G, Martino G (June 2004). "Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects". Neurology. 62 (11): 2092–4. PMID 15184621.